Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1991 1
1992 1
2001 1
2008 2
2009 1
2012 1
2014 1
2018 1
2019 1
2020 1
2021 4
2022 3
2023 2
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, Sahu A, Mei S, Miao B, Sharova T, Alvarez-Breckenridge C, Stocking JH, Kim T, Fadden R, Lawrence D, Hoang MP, Cahill DP, Malehmir M, Nowak MA, Brastianos PK, Lian CG, Ruppin E, Izar B, Herlyn M, Van Allen EM, Nathanson K, Flaherty KT, Sullivan RJ, Kellis M, Sorger PK, Boland GM. Liu D, et al. Among authors: fadden r. Nat Med. 2021 Jun;27(6):985-992. doi: 10.1038/s41591-021-01331-8. Epub 2021 May 3. Nat Med. 2021. PMID: 33941922 Free PMC article.
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME, Wang Q, Seethapathy H, Moreno D, Harden D, Smith RN, Rosales IA, Colvin RB, Chute S, Cornell LD, Herrmann SM, Fadden R, Sullivan RJ, Yang NJ, Barmettler S, Wells S, Gupta S, Villani AC, Reynolds KL, Farmer J. Sise ME, et al. Among authors: fadden r. J Immunother Cancer. 2023 Jan;11(1):e006222. doi: 10.1136/jitc-2022-006222. J Immunother Cancer. 2023. PMID: 36657813 Free PMC article.
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Chen ST, et al. Among authors: fadden r. J Immunother Cancer. 2024 Apr 10;12(4):e007675. doi: 10.1136/jitc-2023-007675. J Immunother Cancer. 2024. PMID: 38599660 Free PMC article.
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.
Seethapathy H, Lee MD, Strohbehn IA, Efe O, Rusibamayila N, Chute DF, Colvin RB, Rosales IA, Fadden RM, Reynolds KL, Sullivan RJ, Kaufman HL, Jhaveri KD, Sise ME. Seethapathy H, et al. Among authors: fadden rm. Nephrol Dial Transplant. 2022 Feb 25;37(3):507-514. doi: 10.1093/ndt/gfaa372. Nephrol Dial Transplant. 2022. PMID: 33355659 Free PMC article.
Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma.
Wang Q, Strohbehn IA, Zhao S, Seethapathy H, Strohbehn SD, Hanna P, Lee M, Fadden R, Sullivan RJ, Boland GM, Reynolds KL, Sise ME. Wang Q, et al. Among authors: fadden r. Kidney Int Rep. 2022 Sep 8;7(11):2517-2521. doi: 10.1016/j.ekir.2022.08.030. eCollection 2022 Nov. Kidney Int Rep. 2022. PMID: 36531890 Free PMC article. No abstract available.
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma.
Seethapathy H, Bates H, Chute DF, Strohbehn I, Strohbehn S, Fadden RM, Reynolds KL, Cohen JV, Sullivan RJ, Sise ME. Seethapathy H, et al. Among authors: fadden rm. Kidney Med. 2020 Apr 18;2(3):373-375. doi: 10.1016/j.xkme.2020.01.012. eCollection 2020 May-Jun. Kidney Med. 2020. PMID: 32734258 Free PMC article. No abstract available.
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW, Wan G, Nguyen N, Rashdan H, Zhang S, Chen W, Cohen S, Boland GM, Sullivan RJ, Fadden RM, Kaufman HL, Kwatra SG, LeBoeuf NR, Semenov YR. Leung BW, et al. Among authors: fadden rm. J Am Acad Dermatol. 2023 Jun;88(6):1265-1270. doi: 10.1016/j.jaad.2023.02.017. Epub 2023 Mar 21. J Am Acad Dermatol. 2023. PMID: 36944564 Free PMC article.
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, Yang X, Wei X, Quach HT, Cann CG, Zhang MZ, Pallan L, Harvey C, Kim MS, Kasumova G, Sharova T, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Frederick DT, Flaherty KT, Long GV, Menzies AM, Sullivan RJ, Boland GM, Johnson DB, Guo J. Bai X, et al. Among authors: fadden rm. Br J Dermatol. 2022 Sep;187(3):401-410. doi: 10.1111/bjd.21241. Epub 2022 May 20. Br J Dermatol. 2022. PMID: 35293617
25 results